Compare VS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VS | TOVX |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 7.3M |
| IPO Year | N/A | 2006 |
| Metric | VS | TOVX |
|---|---|---|
| Price | $1.19 | $0.20 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.7K | ★ 2.6M |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,179,348.00 | N/A |
| Revenue This Year | $3,459.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2281.70 | N/A |
| 52 Week Low | $1.15 | $0.20 |
| 52 Week High | $3.79 | $2.08 |
| Indicator | VS | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 32.94 | 38.42 |
| Support Level | $1.20 | $0.21 |
| Resistance Level | $1.47 | $0.24 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 18.41 | 2.42 |
Versus Systems Inc offers a suite of proprietary business-to-business software tools that are meant to drive user engagement through gamification and rewards. These tools allow its partners to offer in-game prizes and rewards, including merchandise, coupons, digital goods, and sweepstakes entries - inside their websites, their venues, or their streaming media content. Its customers are mostly sports teams, venues, and advertising agencies, which typically use its products as part of their live events or as part of an advertising campaign with the goal of engaging fans, increasing consented first-party data, and increasing sales. The company operates in Canada and the USA.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.